The release of data on the treatment of cancer electric field in Asia is expected to rewrite the clinical treatment of gliomas in China.

(Health Times reporter Ko Xiaoxuan)
. Recently, at the 16th Annual Meeting of the Asian Conference on Neuro-Oncology (ASNO), the results of the global phase III critical clinical study EF-14 Asian population analysis data for patients with newly diagnosed glioblastoma combined with pyrethroid chemotherapy were released, confirming that the combined use of tumor electric field therapy on the basis of chemotherapy can significantly extend the total survival of GBM patients in Asia, and the median survival, one-year and two-year survival rates of Asian patients were even more significantly extended.
", at present, the treatment of glioma in China is mainly surgery, radiotherapy and chemotherapy, but the existing therapeutic efficacy is still not ideal, especially glioblastoma patients five-year survival rate of only 5%. As a clinician, i am eager to have new weapons that can effectively prolong patient survival time," said Ma Wenbin, vice chairman of the Glioma Professional Committee of the Chinese Association of Cancer And Cancer Society and a professor at the Beijing Concord Hospital of the Chinese Academy of Medical Sciences."In recent years, the targeted and immunotherapy of other tumor treatments have failed in both the treatment of gliomas, and the release of this Asian data confirms that on the basis of the absence of cognitive impairment, tumor electro-field therapy has the advantages of improving patients' median progression-free survival, total survival and quality of life, giving clinicians and patients more confidence," said
Ma Wenbin.
it is known that the EF-14 study is an international phase III multicenter clinical study for newly diagnosed GBM patients, and based on its findings, the FDA approved tumor electric field therapy for newly diagnosed glioblastoma in adult patients. Ef-14 overall population results showed that tumor electro-field therapy and TMZ combination therapy significantly improved the patient's progression-free and total survival compared to tMZ chemotherapy, with the patient's five-year total survival rate increased from 5% to 13%, and the median total survival period increased from 16 months to 20.9 months.
the EF-14 study involved a total of 39 Asian patients in eight Korean clinical centers, and the results showed that the prognosis of Asian patients was very close to that of the entire EF-14 study population, while the increase in median survival, one-year and two-year survival rates in Asian patients was even more pronounced. The median progression-free survival of patients treated with Optune/TMZ was 6.2 months, while the median total survival of TMZ patients was 4.2 months (p.67), while the median total survival of the former was significantly longer than the latter (27.2 months vs 15.2 months, 95% CI: 7.5-24.1).
reporters learned that tumor electric field therapy is the use of a specific electric field frequency to interfere with tumor cell division, inhibit tumor growth and cause the death of cancer cells affected by the electric field. In Chinese mainland, the State Drug Administration has accepted applications for the marketing of Optune, a cancer electric field treatment product® for the treatment of glioblastoma, and has recently been granted an innovative medical device qualification. Internationally, tumor electro-field therapy has been approved for glioblastoma treatment in the United States, Europe, Japan and Hong Kong, China."Based on excellent clinical data on tumor electro-field therapy, it has the potential to fundamentally change the way patients with glioblastoma in China are treated," said Professor Ma Wenbin,
. Future electro-field therapy may be combined with surgery, systemic therapy and radiotherapy, becoming an important part of the comprehensive treatment and management of solid tumor patients, hoping to benefit Chinese mainland patients as soon as possible. "
.